FDA’s Dry January: Little Novel Application Activity, But That Doesn’t Mean No Fun

 
• By Bridget Silverman

US FDA’s drugs center posted one of its lowest monthly approval counts of original applications in January, but new indications filled the gap, including new claims for Merck’s Keytruda, Takeda immunoglobulins, and Sanofi/Regeneron’s Dupixent.

Dry January
Sponsors better hope that FDA is not starting a new habit. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers